SCHEMBL29935596

SCHEMBL29935596

CC(C)(C)OC(=O)NC12CCC(CCO)(CC1)C2

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.37
FOLH1 Q04609 1/20 0.36
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
DPP8 Q6V1X1 3/20 0.34
DPP9 Q86TI2 3/20 0.34
CTSL P07711 1/20 0.33
APLNR P35414 1/20 0.32
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31
CTSK P43235 3/20 0.31
CACNA1H O95180 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA7 P43166 1/20 0.30
DGAT1 O75907 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14476417 0.91 TDP1 (0.39) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL19373473 0.89 FOLH1 (0.43) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL14476349 0.88 MEN1 (0.37) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL29709304 0.84 MEN1 (0.37) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL23160914 0.83 FOLH1 (0.34) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL16244106 0.82 MEN1 (0.34) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL15979024 0.81 MEN1 (0.39) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL18697061 0.80 MEN1 (0.44) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL31375880 0.80 TDP1 (0.45) TDP1FOLH1MEN1MAPK1KMT2A
SCHEMBL29419561 0.79 CTSL (0.39) FOLH1MEN1MAPK1KMT2ADPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2024-11-14 US disclosed
EP-4059934-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS Novartis AG (CH) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 TDP1 2371/4885FOLH1 3439/4885MEN1 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.